First Regen Med Investor Day Takes Place April 17, 2013 in New York City
WASHINGTON, Dec. 19, 2012 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced its first Regen Med Investor Day will take place on April 17, 2013. Co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group, this one-day meeting will provide institutional, strategic and venture investors' unique insight into the investment hypothesis for regenerative medicine-based therapeutics and tools.
ARM's Regen Med Investor Day will include presentations by key opinion leaders in the industry, an analyst panel featuring top life science investment experts as well as presentations by up to 20 U.S. and European regenerative medicine companies. The meeting will begin at 9:00 am, and will be held in New York City.
"Burrill & Company is pleased to co-host this event, which brings together leading investors with companies commercializing therapies that have the potential to transform the way we think about diseases, as well as aging," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused on the life sciences. "It is an exciting time to be investing in this transformative sector and this meeting provides a unique opportunity to connect these innovators to capital."
"Regenerative medicine has the potential to truly revolutionize healthcare and, therefore, represents a unique investment opportunity. The field has made incredible progress in recent years. It is our hope that this meeting will help the investment community to better understand the industry as well as highlight the key value creating events of leading companies in the sector," said Ed Field, Chief Operating Officer at Cytomedix, and Chair of ARM's Capital Formation Committee.
Further details of the agenda and presenting companies will be released in coming weeks. For additional information about the Regen Med Investor Day, please contact Laura Parsons at email@example.com. Registration is complimentary for credentialed investors and members of the media.
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.
SOURCE Alliance for Regenerative Medicine